The Comet Assay – A valuable tool for Cancer Research

Supported by:

18 February 2016

Supported by:

18 February 2016

Comet Assay

Research into cancer diagnosis and treatment has been at the forefront of scientific discovery for most of the recent past. Many of the drugs designed to combat cancer target genomic DNA, effectively causing DNA damage within these cells which is then thought to be responsible for killing the cancer cell.

This webinar presents real-world methods and examples of how to monitor and assess DNA damage in these cells using the Comet Assay and an insight into the software used to carry out this analysis – Komet.

Keynote Speakers

Dr. George D. Jones, Deputy Head of Department of Cancer Studies, University of Leicester

Dr George D. Jones Dr. Jones leads the Radiation & Oxidative Stress (ROS) group, Dept. Cancer Studies, University of Leicester. The group’s research aims to elucidate mechanisms responsible for the deleterious effects of radiation and oxidative stress.

For radiation and many chemotherapeutic drugs, genomic DNA is the primary cellular target for their deleterious biological effects; indeed it is the DNA damage induced which is thought responsible for killing of the cancer cells.

To better understand, judge and improve treatment efficacy, the purpose of their research is to explore mechanisms to enhance these damaging interactions and to develop methods and biomarkers for the accurate measurement of DNA damage in vitro and in vivo.

In this presentation, Dr. Jones illustrates how they use the Comet assay to assess DNA damage in vitro and in vivo.

Dr. Orla Hanrahan, Application Specialist, Andor

Dr Orla HanrahanDr. Hanrahan has worked with Andor Technology as an Application Specialist in Life Science for the past 5 years. Previous to this she completed a PhD in Biochemistry and managed a microscopy facility for 5 years.

Dr. Hanrahan presents the key features and benefits of Komet software for the acquisition and analysis of The Comet Assay. Komet is the most highly referenced Comet Assay analysis solution in research publications and is so versatile it can score comets either during a live acquisition using the many cameras it supports or from files that have been saved and need scoring and analysis.

Supported by Andor

Andor Technology Ltd (Andor) is based in Belfast, Northern Ireland and operates at the high-value end of the global scientific digital camera market. Andor was setup in 1989 out of Queen’s University in Belfast, and now employs over 400 people in 16 offices worldwide and distributes its products to 10,000 customers in 55 countries.
Find out more: www.andor.com

Related organisations

Related diseases & conditions

2 responses to “The Comet Assay – A valuable tool for Cancer Research”

  1. salwa ali says:

    please repeat discussion

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.